Cargando…
Evolution of CD8(+) T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
Engineered T cell receptor T (TCR-T) cell therapy has facilitated the generation of increasingly reliable tumor antigen-specific adaptable cellular products for the treatment of human cancer. TCR-T cell therapies were initially focused on targeting shared tumor-associated peptide targets, including...
Autores principales: | Sun, Yimo, Li, Fenge, Sonnemann, Heather, Jackson, Kyle R., Talukder, Amjad H., Katailiha, Arjun S., Lizee, Gregory |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469972/ https://www.ncbi.nlm.nih.gov/pubmed/34572028 http://dx.doi.org/10.3390/cells10092379 |
Ejemplares similares
-
Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma
por: Li, Fenge, et al.
Publicado: (2023) -
Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules
por: Jackson, Kyle R, et al.
Publicado: (2022) -
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers
por: Bradley, Sherille D., et al.
Publicado: (2020) -
Enhancing Efficacy of TCR-engineered CD4(+) T Cells Via Coexpression of CD8α
por: Anderson, Victoria E., et al.
Publicado: (2023) -
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
por: Li, Fenge, et al.
Publicado: (2021)